CN102423384A - 一种治疗肺癌的中药制剂及其制备方法 - Google Patents
一种治疗肺癌的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN102423384A CN102423384A CN2011104088056A CN201110408805A CN102423384A CN 102423384 A CN102423384 A CN 102423384A CN 2011104088056 A CN2011104088056 A CN 2011104088056A CN 201110408805 A CN201110408805 A CN 201110408805A CN 102423384 A CN102423384 A CN 102423384A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- lung cancer
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 201000005202 lung cancer Diseases 0.000 title abstract description 12
- 208000020816 lung neoplasm Diseases 0.000 title abstract description 12
- 239000003390 Chinese drug Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 claims abstract description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 10
- 241000283956 Manis Species 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 239000009286 sanguis draxonis Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 43
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000289692 Myrmecophagidae Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- JEDBBFHVVHKMKS-UHFFFAOYSA-N 5,7-dimethoxy-8-(3-methylbut-2-enoyl)chromen-2-one Chemical compound C1=CC(=O)OC2=C(C(=O)C=C(C)C)C(OC)=CC(OC)=C21 JEDBBFHVVHKMKS-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 benzene penta phenol phosphorus carboxylic acid Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
小鼠组别 | 1 | 2 | 3 | 4 | 5 | 6 |
染色部位 | 白 | 头 | 背 | 尾 | 左前 | 左中 |
组别 | 组名 | 给药剂量 | 给药方式 |
1 | 模型组 | — | 灌胃 |
2 | 本发明中药组合物低剂量组 | 20 mg/kg | 灌胃 |
3 | 本发明中药组合物高剂量组 | 40 mg/kg | 灌胃 |
4 | 金复康口服液组 | 5ml/kg | 灌胃 |
组别 | 剂量 | 瘤重 | 抑瘤率% |
模型组 | - | 4.23±0.89 | - |
中药组合物低剂量组 | 20 mg/kg | 3.07±1.03▲ | 27.4 |
中药组合物高剂量组 | 40 mg/kg | 2.68±0.54▲ | 36.6 |
金复康口服液组 | 5ml/kg | 2.23±0.38▲ | 47.3 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104088056A CN102423384B (zh) | 2011-12-11 | 2011-12-11 | 一种治疗肺癌的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104088056A CN102423384B (zh) | 2011-12-11 | 2011-12-11 | 一种治疗肺癌的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102423384A true CN102423384A (zh) | 2012-04-25 |
CN102423384B CN102423384B (zh) | 2013-04-17 |
Family
ID=45957471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011104088056A Expired - Fee Related CN102423384B (zh) | 2011-12-11 | 2011-12-11 | 一种治疗肺癌的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102423384B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716382A (zh) * | 2012-07-15 | 2012-10-10 | 杨献华 | 一种治疗肺癌的中药组合物及其制备方法 |
CN105902865A (zh) * | 2016-06-12 | 2016-08-31 | 潘纪红 | 一种治疗肿瘤的中药制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217928A (zh) * | 1997-11-20 | 1999-06-02 | 黄延娜 | 一种治疗上皮组织发生肿瘤的中药制剂及制备方法 |
-
2011
- 2011-12-11 CN CN2011104088056A patent/CN102423384B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217928A (zh) * | 1997-11-20 | 1999-06-02 | 黄延娜 | 一种治疗上皮组织发生肿瘤的中药制剂及制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716382A (zh) * | 2012-07-15 | 2012-10-10 | 杨献华 | 一种治疗肺癌的中药组合物及其制备方法 |
CN105902865A (zh) * | 2016-06-12 | 2016-08-31 | 潘纪红 | 一种治疗肿瘤的中药制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102423384B (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100363022C (zh) | 一种具有免疫调节作用的药物组合物及其制备方法 | |
WO2013071727A1 (zh) | 抗肿瘤的中药组合物 | |
CN102861284B (zh) | 一种治疗非小细胞肺癌的中药复方制剂及其制备方法 | |
CN102861193B (zh) | 一种治疗胃癌的中药组合物 | |
KR20190124197A (ko) | 종양 치료용 한약 조성물 및 그 제조방법 및 응용 | |
CN115120689A (zh) | 欣力康复方制剂在制备药物中的应用 | |
CN104940479A (zh) | 一种治疗ad病的中药组合物 | |
CN102389559B (zh) | 一种中药组合物及其作为放疗增敏剂的应用 | |
CN101711848A (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN102579803A (zh) | 一种治疗化疗后白细胞减少症的药物及其制备方法 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN111481638A (zh) | 一种治疗溃疡性结肠炎的中药灌肠制剂及其制备方法 | |
CN101347543A (zh) | 一种中药组合物及其制备方法 | |
CN102872385B (zh) | 一种治疗晚期胃癌的复方中药组合物及其制备方法和应用 | |
CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
CN103191267B (zh) | 一种治疗肝癌的中药组合物 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN103463253B (zh) | 一种癌症术后防复发的真菌药物及其生产方法 | |
CN102716382A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN102949681B (zh) | 一种预防或治疗感冒的组合物及其制备方法 | |
CN104096065A (zh) | 一种治疗非小细胞肺癌的中药组合物 | |
CN103520684A (zh) | 一种降血糖的中药复合物 | |
CN115252729B (zh) | 一种治疗糖尿病的中药组合物及其应用 | |
CN114404490B (zh) | 用于治疗肿瘤放化疗后白细胞减少症的中药及制备方法 | |
CN114159533B (zh) | 一种治疗多重耐药细菌感染的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Fan Zhiyan Inventor after: Hou Jianmei Inventor before: Lu Zhihe |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LU ZHIHE TO: FAN ZHIYAN HOU JIANMEI |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANTONG HAIERS PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XU CONGYU Effective date: 20131105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 226499 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131105 Address after: 226499, 9, Chen Gao Industrial Park, Rudong County, Jiangsu, Nantong Patentee after: NANTONG HAIERS PHARMACEUTICAL Co.,Ltd. Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Patentee before: Xu Congyu |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130417 |